top of page

Biopharma Daily Stock Updates - 07/01/21

$XBI $138.5 +2.3%

 

Covid Updates

$MRNA +0.1% Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency. source


$OYST -0.7% Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpinicline) Against SARS-CoV-2 Virus and Variants. source


$ VALN +2.3% Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate. source


Pipeline Updates

$SCPH +17.0% scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®. source


$KRYS +5.5% Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis. source


$PBYI +2.3% FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer. source


$CTXR -25.3% Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned. source


$HRTX -2.4% Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours. source


$IMAB +0.6% I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio. source


$CLSN -1.6% Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer. source


$RFL +6.4% Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML). source


$ALRN +4.8% Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). source


$ACHL +1.4% Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer. source


$EYPT -0.4% EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association. source


$CNCE -3.8% Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit. source


$MCRB -5.2% Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement. source


$DTIL +1.1% Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma. source


$NGM +6.6% NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases. source


$IMUX +5.5% Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis. source


$ARQT -2.9% Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo. source


$ORTX -2.3% & PHAR +2.0% Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema. source


$JAZZ +2.0% Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. source


$SLS -16.0% On 6/30 SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer. source


Financial Updates

$AFMD -11.7% Affimed Reports First Quarter 2021 Financial Results and Highlights Operational Progress. source


$BSGM -11.7% BioSig Announces Proposed Public Offering of Common Stock. source


$KYMR +15.6% Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock. source


$ALGS -17.3% Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock. source


$SPRO +17.4% Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206. source

 

Posted by FS

0 comments
bottom of page